MCLEAN, Va., May 19, 2014 (GLOBE NEWSWIRE) -- Personalized Cancer Therapy, Inc. (d.b.a. Perthera), a precision cancer therapy firm, today announces that it will be hosting a networking breakfast and educational session on Monday, June 2 from 6:45-7:45 a.m. for those in attendance of the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The breakfast event will take place in the Regency C Ballroom of Hyatt Regency McCormick Place, which is adjacent to the convention center and will feature a presentation by Michael Pishvaian, MD, PhD, Phase 1 Program Director at Lombardi Comprehensive Cancer Center, Georgetown University on "Navigating the Sea of Big Data: Transforming Molecular Analyses of Cancer Patients into Actionable Treatment Decisions."1
To confirm your attendance at the breakfast event, please register online at www.perthera.com/breakfastmeeting.
"As personalized medicine transforms patient care and scientific advances improve access to molecular data, it is vital that oncologists understand how best to effectively use the available data in ways that will provide the highest quality treatment to their patients," said Dr. Pishvaian. "My goal is for all attendees to take away with them these best practices for turning this newfound data into actionable treatment decisions for today's oncologists and their patients."
The 50th anniversary ASCO Annual Meeting will be held at the McCormick Place Convention Center in Chicago, Friday, May 30 to Tuesday, June 3, and will attract more than 25,000 oncology professionals from around the world. In addition to the networking breakfast meeting, Perthera will exhibiting in booth #4040 and have executives on hand during the conference to meet personally with attendees interested in learning more about the role of personalized medicine in cancer treatment, as well as answer the most pressing cancer treatment questions in the industry today.
Dr. Pishvaian is a gastro-intestinal oncologist focused on translational cancer care. His background as an MD and a PhD has put him in a unique position to understand the basic science of targeted therapies in oncology, while providing him with the training as a compassionate clinical oncologist. His area of focus is the development of rational combinations of novel, targeted anti-cancer agents, with a particular emphasis on pancreatic cancer, and refractory colorectal cancer. Dr. Pishvaian is principal investigator on several clinical trials, including Phase I trials, and Phase II trials for patients with colorectal and pancreatic cancer. Each of Dr. Pishvaian's trials are heavily focused on the acquisition and analysis of patient tumor biopsies to identify molecular markers that are predictive of response to therapy.
Based in McLean, Virginia, Personalized Cancer Therapy, Inc. (d.b.a. Perthera) offers a concierge service that helps oncologists identify the best treatment options for patients employing chemotherapy to fight cancer. The company uses targeted molecular testing and its proprietary Perthera Expert Oncology technology of molecular cancer profiles to recommend the latest treatment therapies individualized for each patient and his or her physician.
1Not an official event of the 2014 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or Conquer Cancer Foundation.
Press contact Dave Anderson, on behalf of Perthera 678-401-2991